Trials / Completed
CompletedNCT02455271
Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients
Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients (Study LUN02T)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 438 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and efficacy of administration of eszopiclone for 6 months in insomnia participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eszopiclone | The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2015-03-30
- Completion
- 2015-12-22
- First posted
- 2015-05-27
- Last updated
- 2018-09-07
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02455271. Inclusion in this directory is not an endorsement.